Malignant Hyperthermia Syndrome: A Clinical Case Report

EJIFCC. 2021 Jun 29;32(2):286-291. eCollection 2021 Jun.

Abstract

Malignant hyperthermia is a pharmacogenetic disorder. It manifests as a hypercatabolic skeletal muscle syndrome linked to inhaled volatile anesthetics or depolarizing muscle relaxants. Its clinical signs and symptoms are tachycardia, hyperthermia, hypercapnia, acidosis, muscle rigidity, rhabdomyolysis, hyperkalemia, arrhythmia and renal failure. Mortality without specific treatment is 80% and decreases to 5% with the use of dantrolene sodium. This article presents the case of a 39-year-old patient admitted to the Intensive Care Unit for malignant hyperthermia after surgery for septoplasty plus turbinoplasty.

Keywords: dantrolene; desflurane; inhaled anesthetics; malignant hyperthermia; ryanodine; succinylcholine.

Publication types

  • Case Reports